Norris Perne & French LLP MI Purchases 3,028 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Norris Perne & French LLP MI lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 2.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 129,082 shares of the medical research company's stock after purchasing an additional 3,028 shares during the quarter. Charles River Laboratories International comprises approximately 1.5% of Norris Perne & French LLP MI's portfolio, making the stock its 28th largest holding. Norris Perne & French LLP MI owned approximately 0.26% of Charles River Laboratories International worth $19,429,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Rothschild Investment LLC grew its position in Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after acquiring an additional 144 shares in the last quarter. Optiver Holding B.V. purchased a new position in Charles River Laboratories International in the fourth quarter worth $37,000. GeoWealth Management LLC grew its position in Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after acquiring an additional 190 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new position in Charles River Laboratories International in the fourth quarter worth $48,000. Finally, Tortoise Investment Management LLC grew its position in Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after acquiring an additional 115 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president now owns 19,513 shares of the company's stock, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

CRL has been the subject of several research reports. Barclays upped their target price on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective on the stock in a research note on Wednesday, May 14th. Mizuho reduced their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. Evercore ISI raised Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price objective on the stock in a research note on Thursday, May 8th. Finally, Robert W. Baird raised their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $171.85.

Charles River Laboratories International Stock Up 1.4%

Charles River Laboratories International stock traded up $2.08 during trading hours on Friday, hitting $147.37. 1,542,754 shares of the stock traded hands, compared to its average volume of 1,013,591. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The firm's 50-day moving average price is $131.74 and its two-hundred day moving average price is $155.26. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The company has a market cap of $7.24 billion, a PE ratio of -226.73, a PEG ratio of 4.55 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The company had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. During the same period in the prior year, the firm earned $2.27 earnings per share. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).